Protara Therapeutics (TARA) Receives a Buy from TD Cowen

Tip Ranks
2025.11.20 22:15
portai
I'm PortAI, I can summarize articles.

TD Cowen analyst Stacy Ku maintained a Buy rating on Protara Therapeutics, setting a price target of $30.00, while the stock closed at $6.71. The consensus among analysts is a Strong Buy with a $25.00 average price target, indicating a 272.58% upside. Oppenheimer also reiterated a Buy rating with a $25.00 target.

TD Cowen analyst Stacy Ku maintained a Buy rating on Protara Therapeutics yesterday and set a price target of $30.00. The company’s shares closed today at $6.71.

TipRanks Black Friday Sale

  • Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
  • Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off

Ku covers the Healthcare sector, focusing on stocks such as LENZ Therapeutics, BioCryst, and KalVista Pharmaceuticals. According to TipRanks, Ku has an average return of 8.2% and a 57.89% success rate on recommended stocks.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Protara Therapeutics with a $25.00 average price target, a 272.58% upside from current levels. In a report released today, Oppenheimer also reiterated a Buy rating on the stock with a $25.00 price target.

Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
© 2025 Longbridge｜Disclaimer